ArticleBMC infectious diseases2024

Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study.

Myriam Drysdale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.